Biotech-Depot – Teil 1

In meinem Beitrag „FDA-Approval“ findet sich folgendes Zitat:

„Buying NASDAQ Assets 60 days prior to the announcement date and selling them 5 days prior to the announcement date results in an average HPR of 182.68%, clearly outperforming both the ^NBI and ^IXIC. The distribution of HPRs is not symmetrical; returns larger than 600% could be obtained using this trading strategy. This trading strategy never results in negative returns and almost always performs better than the HPR obtained by investing in ^NBI or ^IXIC. Consequently, selling NASDAQ Assets 60 days prior to the announcement date and buying them back 5 days prior to the announcement date results in a loss larger than 99 %.“

In einer Annäherung an das Thema habe ich ein Muster-Depot aufgesetzt, das 20 Unternehmen enthält, die

Weiterlesen „Biotech-Depot – Teil 1“